Proton Therapy for Recurrent Nasopharyngeal Carcinoma

Summary

The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and retrospective studies, lacking high-level evidence-based medical evidence. The conduct of this study will explore the safety and efficacy of intensity-modulated proton radiotherapy for recurrent NPC and provide more high-quality evidence-based medical evidence for proton therapy of recurrent cancer.

Eligibility

Inclusion Criteria:

1. Non-metastatic squamous cell carcinoma of the nasopharynx with biopsy confirmation, at stage ≥ T2b and/or with positive lymph nodes, (2) Pathological type WHO I-III
2. PS score (according to Eastern Cooperative Oncology Group (ECOG) standard) 0-1.

   Age ≥ 18 years.
3. Expected survival period ≥ 6 months
4. Before treatment, evaluate the tumor range and size of the patient.
5. Nutritional and general physical condition must be able to tolerate the recommended radiotherapy and chemotherapy.

Exclusion Criteria:

1. Evidence of distant metastasis in stage IVc
2. Patients with isolated recurrence of cervical lymph nodes;
3. Patients have participated in other interventional trials for tumors
4. Having suffered from other malignant tumors within 5 years (excluding melanoma skin cancer) or tumors originating from the head and neck region Untreated active infections

Conditions2

Browse More Trials